Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer’s disease: A systematic review

BACKGROUND: Lecanemab is the latest monoclonal antibody that targets beta-amyloid approved exclusively for treatment of Alzheimer’s disease with mild cognitive impairment or mild dementia. This article aims to provide a systematic review of the efficacy, and safety of lecanemab in slowing clinical d...

Descripción completa

Detalles Bibliográficos
Autores principales: Chowdhury, Selia, Chowdhury, Nurjahan Shipa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617290/
https://www.ncbi.nlm.nih.gov/pubmed/37902139
http://dx.doi.org/10.1177/03946320231209839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617290/
https://www.ncbi.nlm.nih.gov/pubmed/37902139
http://dx.doi.org/10.1177/03946320231209839

Ejemplares similares